plerixafor

May 10, 2024

X4 Pharmaceuticals has gained approval for its first product, XOLREMDI (mavorixafor), marking its entrance into the commercial rare disease market. The FDA approved mavorixafor on April 29, 2024, specifically for patients aged 12 and above diagnosed with WHIM syndrome (characterized by warts, hypogammaglobulinemia,...

Oct 06, 2017

C-X-C chemokine receptors (CXCR) is a family of G protein-coupled receptors that comprises of a large subfamily of the rhodopsin superfamily of 7-transmembrane domain receptors. Two types of chemokine receptors have been identified including monogamous chemokine receptors (bind to only one specific chemokine) and pr...